Nanomedical Diagnostics Agile R100 Graphene Biosensor Characterizes Difficult-to-Study MYC Oncoprotein for Cancer Research
Using data gathered by Agile R100, a kinetic binding assay system, scientists from Dr. Kim Janda’s laboratory at the Scripps Research Institute developed a new series of compounds with the potential to down-regulate the transcriptional activities of MYC. San Diego, CA...Nanomedical Diagnostics Launches New Graphene Biosensor for Validating Primary Screen Hits During Early Stage Drug Discovery
Nanomedical Diagnostics, leading manufacturer of graphene biosensors that accelerate pharmaceutical development, launches the new Super Amine-Immobilization Biosensor – SCOOH, for use with the company’s optics-free assay troubleshooting system, Agile R100. The new...![Nanomedical Diagnostics Releases Report on Affinity Ranking for Hit Validation](https://www.unitedbiochannels.com/wp-content/uploads/2018/05/nanomedPR.png)
Nanomedical Diagnostics Releases Report on Affinity Ranking for Hit Validation
Labels can get in the way of accurate ranking for tight-binding interactions. Nanomedical Diagnostics presents biochemists a possible solution. SAN DIEGO (PRWEB) May 08, 2018 Nanomedical Diagnostics, leading manufacturer of graphene biosensors that accelerate...![Industry News](https://www.unitedbiochannels.com/wp-content/uploads/2017/11/hands.jpg)